Tennessee is currently home to 1997 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067
Recruiting
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/08/2024
Locations: SCRI Oncology Partners (formerly Tennessee Oncology), Nashville, Tennessee
Conditions: Advanced or Metastatic NRAS-mutant Melanoma
Register for Updates
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891
Recruiting
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the part... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
05/08/2024
Locations: Sarah Cannon Research Institute Site Number : 8400003, Nashville, Tennessee
Conditions: Chronic Graft Versus Host Disease
Register for Updates
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion crite... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
05/08/2024
Locations: HOPE Neurology Site Number : 8400019, Knoxville, Tennessee
Conditions: Multiple Sclerosis
Register for Updates
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Gender:
All
Ages:
Between 40 years and 90 years
Trial Updated:
05/08/2024
Locations: Tennessee Center for Clinical Trials, Tullahoma, Tennessee
Conditions: Heart Failure
Register for Updates
Study of DF6215 in Patients With Advanced Solid Tumors
NCT06108479
Recruiting
DF6215-001 is a study of a modified human cytokine (interleukin-2; IL-2) that retains the ability to bind to a certain part of the IL-2 receptor on a subset of white blood cells (lymphocytes), which can help recognize and kill tumor cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors. The second phase, Phase 1b, will include a dose expansion using the best dose selected from the first phase of the study... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Solid Tumor, Adult
Register for Updates
The Society for Obstetric Anesthesia and Perinatology Research Network General Anesthesia Registry
NCT06030063
Recruiting
The SOAP registry is a prospective, multicenter, electronic registry. The goal is to investigate the indications, mode of airway management, predisposing factors, and obstetric and anesthetic outcomes of pregnant patients who receive general anesthesia for cesarean delivery.
Gender:
Female
Ages:
Between 15 years and 55 years
Trial Updated:
05/08/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Cesarean Delivery, General Anesthesia
Register for Updates
Nectero EAST System Clinical Study
NCT06001918
Recruiting
The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demonstrate efficacy of the product for stabilization of these small to mid-sized AAA.The study will compare the treatment group to the typical standard of care for these patients, surveillance. All subjects will be followed... Read More
Gender:
All
Ages:
Between 21 years and 85 years
Trial Updated:
05/08/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Abdominal Aortic Aneurysm
Register for Updates
Safety and Tolerability of GTX-104 Compared With Oral Nimodipine in Patients With aSAH
NCT05995405
Recruiting
The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Aneurysmal Subarachnoid Hemorrhage (aSAH)
Register for Updates
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551
Recruiting
The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any fractures at 12-months and change in lumbar spine bone mineral density (BMD) Z-score at 6-months.
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
05/08/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Osteogenesis Imperfecta
Register for Updates
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356
Recruiting
The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/08/2024
Locations: University of Tennessee Medical Center Knoxville, Knoxville, Tennessee
Conditions: Non-Small Cell Lung Cancer (NSCLC)
Register for Updates
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
05/08/2024
Locations: Cumberland Skin Center, Hermitage, Tennessee
Conditions: Atopic Dermatitis
Register for Updates
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
NCT05800964
Recruiting
The primary objective of this study is to: Evaluate the safety and tolerability of AMG 305 in adult participants Determine the optimal biologically active dose (OBD), at or below the maximum tolerated dose (MTD) with MTD 1 as the maximum tolerated starting dose and MTD 2 as the maximum tolerated target dose Determine the recommended phase 2 dose (RP2D)
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/08/2024
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Advanced Solid Tumors
Register for Updates